5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The IRE1 ER stress sensor activates natural killer cell immunity in part by regulating c-Myc

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Natural killer (NK) cells are critical mediators of host immunity to pathogens. Here, we demonstrate that the ER stress sensor inositol-requiring enzyme 1 (IRE1α) and its substrate transcription factor X-box-binding protein 1 (XBP1) drive NK cell responses against viral infection and tumors in vivo. IRE1α-XBP1 were essential for expansion of activated mouse and human NK cells and are situated downstream of the mTOR signaling pathway. Transcriptome and chromatin immunoprecipitation analysis revealed c-Myc as a novel and direct downstream target of XBP1 for regulation of NK cell proliferation. Genetic ablation or pharmaceutical blockade of IRE1α downregulated c-Myc, and NK cells with c-Myc haploinsufficency phenocopied IRE1α-XBP1 deficiency. c-Myc overexpression largely rescued the proliferation defect in IRE1α −/− NK cells. Like c-Myc, IRE1α-XBP1 also promotes oxidative phosphorylation in NK cells. Overall, our study identifies a novel IRE1α-XBP1-cMyc axis in NK cell immunity, providing new insight into host protection against infection and cancer.

          Related collections

          Most cited references44

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

          Summary Conventional type 1 dendritic cells (cDC1) are critical for antitumor immunity, and their abundance within tumors is associated with immune-mediated rejection and the success of immunotherapy. Here, we show that cDC1 accumulation in mouse tumors often depends on natural killer (NK) cells that produce the cDC1 chemoattractants CCL5 and XCL1. Similarly, in human cancers, intratumoral CCL5, XCL1, and XCL2 transcripts closely correlate with gene signatures of both NK cells and cDC1 and are associated with increased overall patient survival. Notably, tumor production of prostaglandin E2 (PGE2) leads to evasion of the NK cell-cDC1 axis in part by impairing NK cell viability and chemokine production, as well as by causing downregulation of chemokine receptor expression in cDC1. Our findings reveal a cellular and molecular checkpoint for intratumoral cDC1 recruitment that is targeted by tumor-derived PGE2 for immune evasion and that could be exploited for cancer therapy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

            Summary Checkpoint inhibitors have revolutionized cancer treatment. However, only a minority of patients respond to these immunotherapies. Here, we report that blocking the inhibitory NKG2A receptor enhances tumor immunity by promoting both natural killer (NK) and CD8+ T cell effector functions in mice and humans. Monalizumab, a humanized anti-NKG2A antibody, enhanced NK cell activity against various tumor cells and rescued CD8+ T cell function in combination with PD-x axis blockade. Monalizumab also stimulated NK cell activity against antibody-coated target cells. Interim results of a phase II trial of monalizumab plus cetuximab in previously treated squamous cell carcinoma of the head and neck showed a 31% objective response rate. Most common adverse events were fatigue (17%), pyrexia (13%), and headache (10%). NKG2A targeting with monalizumab is thus a novel checkpoint inhibitory mechanism promoting anti-tumor immunity by enhancing the activity of both T and NK cells, which may complement first-generation immunotherapies against cancer.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              NK cells and cancer: you can teach innate cells new tricks.

              Natural killer (NK) cells are the prototype innate lymphoid cells endowed with potent cytolytic function that provide host defence against microbial infection and tumours. Here, we review evidence for the role of NK cells in immune surveillance against cancer and highlight new therapeutic approaches for targeting NK cells in the treatment of cancer.
                Bookmark

                Author and article information

                Journal
                100941354
                21750
                Nat Immunol
                Nat. Immunol.
                Nature immunology
                1529-2908
                1529-2916
                5 April 2019
                13 May 2019
                July 2019
                13 November 2019
                : 20
                : 7
                : 865-878
                Affiliations
                [1 ]Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
                [2 ]Department of Medicine, and Department of Microbiology and Immunology, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, 02115, USA.
                [3 ]Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
                [4 ]Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
                [5 ]Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
                [6 ]Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA
                [7 ]Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
                [8 ]Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
                [9 ]National Heart Lung and Blood Institute, National Institute of Health. Bethesda, MD 20892, USA
                [10 ]Department of Immunology, University of Toronto, Toronto, Ontario, Canada
                [11 ]Sunnybrook Research Institute, Toronto, Ontario, Canada
                [12 ]Department of Immunology and Microbial Pathogenesis, Weill Cornell Medical College, New York, NY 10065, USA
                Author notes

                Author contributions

                L.H.G. conceptualized the project, and L.H.G and J.C.S provided supervision. L.H.G., J.C.S, H.D. and N.M.A. designed the experiments. H.D. carried out the experiments, and H.D., L.H.G. and J.C.S. analyzed the data. Y.X. performed the bioinformatics analysis. J.C. did the ChIP experiments and analysis under the supervision of X.C. D.S.J.A. and J.R.C. provided critical reagents. H.D., N.M.A. and Y.X. made the figures. H.D. and N.M.A. wrote the original draft. X.C. proposed key experiments and provided critical feedback on the manuscript. J.C.S. and L.H.G. reviewed and edited the manuscript and figures.

                [* ]Correspondence to Laurie H. Glimcher ( laurie_glimcher@ 123456dfci.harvard.edu ) or Joseph C. Sun ( sunj@ 123456mskcc.org ).
                Article
                NIHMS1525854
                10.1038/s41590-019-0388-z
                6588410
                31086333
                7ce1f893-9a50-4373-94e1-09c4b1f6e8a9

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Immunology
                Immunology

                Comments

                Comment on this article